"No man that does not see visions
will ever realize any high hope
or undertake any high enterprise."
15 years of active commitment of a motivated and creative producer of laboratory diagnostics.
2011 June
The former unutilized loft was reconstructed to establish further 500 qm of working area and an attractive breakroom for the Seramun staff.
2010 November
Establishment of a clean room for microarray development
Expansion of laboratory area for research and development and quality control investments.
2009 March
Establishment of a molecular biology laboratory (S1)
2004 December
Establishment of an L2 laboratory to handle human pathogenic agents
2003 December
Start of the production in the new laboratories with a staff of 16, including two medical doctors, one biologist, one biotechnologist and two chemists
2003 November
Movement to the new residence. Certification of the company's quality management system According to DIN EN ISO 9001:2000 and DIN EN ISO 13485:2003 by German federal licensing authority (TÜV Rheinland)
2001 January - 2003 October
Reconstruction of a former charitable home to modern laboratory and administration facilities (floor space 2000 m²)
1999 November
First presentation at MEDICA
1998 October
Certification of the company's quality management system according to DIN EN ISO 9001 by German federal licensing authority (TÜV Rheinland)
1997 May
General license to produce, store and sell in-vitro diagnostic kits according to German federal pharmaceutical law (AMG), issued by Brandenburg state health authority (Landesamt für Soziales und Versorgung des Landes Brandenburg, Abt. Landesgesundheitsamt)
1995 June
Full range of business activities, following construction of development and production facilities (Laboratory size 200 m²)
1994 April
First immunoassay developments and antibody production (Laboratory size 20 m²)
1992 November
Establishment of the company in Dolgenbrodt, Landkreis Dahme / Spreewald, Brandenburg, Germany, Managing director / main Shareholder is Prof. Dr. med. T. Porstmann
Investments: ca. 0.2 Mio EURO
Investments: 2.17 Mio EURO
Own financial contribution:
1.07 Mio EURO
Investments: ca. 0.25 Mio EURO
Investments: ca. 25.000 EURO